# Semaglutide improves knee osteoarthritis independant of weight loss

- Score: 169 | [HN](https://news.ycombinator.com/item?id=46962801) | Link: https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00008-2

### TL;DR
Semaglutide, a GLP‑1 drug best known for weight loss, appears to directly improve knee osteoarthritis: restoring cartilage and reducing joint damage in mice and a small randomized trial, even when weight and calories are tightly controlled. This supports the idea that OA is partly a metabolic/inflammatory disease, not just “wear and tear.” HN discussion splits between skepticism that benefits are truly weight‑independent and enthusiasm about wide-ranging GLP‑1 effects on pain, cravings, mood, and long‑term health, alongside worries about cost and access.

---

### Comment pulse
- Maybe we’ve underestimated weight loss → better metabolism plausibly improves joints, heart, addiction, mood—counterpoint: paper’s controlled-diet arm shows structural benefits without weight change.  
- Biology supports pleiotropy → GLP‑1 receptors in cartilage and brain; data show less inflammation, less ER stress, and cartilage repair beyond mechanical load.  
- Anecdotes: GLP‑1s reduce alcohol use, impulse spending, anxiety, back pain; others see mood worsening. Cost and diabetes-only reimbursement block wider preventive use.

---

### LLM perspective
- View: OA should be reframed as partly metabolic; GLP‑1s look like the first credible disease‑modifying OA drugs.  
- Impact: Could delay joint replacements, reshape obesity/OA guidelines, and blur lines between metabolic, psychiatric, and musculoskeletal treatment.  
- Watch next: Larger, longer RCTs with imaging/biomarkers, head‑to‑head with NSAIDs, plus systematic tracking of mood and addiction outcomes.
